System and method for treating an adverse cardiac condition using combined pacing and drug delivery

ABSTRACT

A system and method of treating an adverse cardiac condition, such as cardiac arrhythmia or a non-arrhythmic event, involves producing, by use of a patient actuatable non-implanted activator, an activation signal in response to a patient sensing a perceived adverse cardiac condition. The method further involves confirming, by an implantable medical device provided within the patient, that the patient is experiencing an actual adverse cardiac condition. A perceivable initiating signal instructing the patient or a physician to commence with a drug delivery regimen to treat the actual cardiac adverse condition is generated by the non-implanted activator. In one approach, the implantable medical device operates in a safe mode of pacing during drug treatment of the actual adverse cardiac condition. In another approach, an appropriate pacing, cardioversion or defibrillation regimen is initiated to treat the actual adverse cardiac condition.

FIELD OF THE INVENTION

The present invention relates generally to implantable medical devicesand, more particularly, to the treatment of cardiac arrhythmia bycombined pacing and drug delivery through use of a non-implantableactivator device in concert with an implantable cardiac managementdevice.

BACKGROUND OF THE INVENTION

Proper cardiac function relies on the synchronized contraction of theheart at regular intervals. When normal cardiac rhythm is initiated atthe sinoatrial node, the heart is said to be in sinus rhythm. However,when the heart experiences irregularities in its coordinatedcontraction, due to electrophysiologic disturbances caused by a diseaseprocess or from an electrical disturbance, the heart is denoted to bearrhythmic. The resulting cardiac arrhythmia impairs cardiac efficiencyand can be life-threatening.

Cardiac arrhythmias originating in the atria of the heart are calledsupra-ventricular tachyarrhythmias (SVTs). SVTs take many forms,including atrial fibrillation and atrial flutter. Both conditions arecharacterized by rapid, uncoordinated contractions of the atria. Besidesbeing hemodynamically inefficient, the rapid contractions of the atriacan also adversely affect the ventricular rate. This occurs when theaberrant impulse in the atria are transmitted to the ventricles. It isthen possible for the aberrant atrial signals to cause irregularventricular activation and even induce ventricular tachyarrhythmias.

Cardiac arrhythmias occurring in the ventricular region of the heart, byway of further example, are called ventricular tachyarrhythmias.Ventricular tachycardia (VTs), for example, are conditions denoted by arapid heart beat, 150 to 250 beats per minute, that has its origin insome abnormal location with the ventricular myocardium. The abnormallocation typically results from damage to the ventricular myocardiumfrom a myocardial infarction. Ventricular tachycardia can quicklydegenerate into ventricular fibrillation (VF). Ventricular fibrillationis a condition denoted by extremely rapid, non synchronous contractionsof the ventricles. This condition is fatal unless the heart is returnedto sinus rhythm within a few minutes.

Pro-arrhythmia has been defined as the provocation of a new arrhythmiaor the aggravation of a pre-existing arrhythmia during therapy with adrug at doses or plasma concentrations below those considered toxic.Suggested criteria for pro-arrhythmia include: the new appearance of asustained ventricular tachyarrhythmia; change from a nonsustained to asustained ventricular tachyarrhythmia; acceleration of tachycardia rate;or the new appearance of a clinically significant bradyarrhythmia orconduction defect. Pro-arrhythmia can be the direct result of a drug'selectrophysiologic effects on conduction velocity, refractoriness, andautomaticity. However, it may also be the result of metabolicabnormalities, changes in autonomic state, or drug/drug interactionsthat amplify or alter the drug's electrophysiologic effects.

SVT Atrial Fibrillation (AF) is the most common arrhythmia in man. AFmay be terminated by defibrillation shocks or by anti-arrhythmic drugs.Defibrillation shocks are successful at terminating AF in the majorityof patients, however, they have physical/psychological side effects ofpain or discomfort, low patient tolerance, and the potential forventricular pro-arrhythmia. Anti-arrhythmic drugs can also be highlysuccessful at terminating AF. However, drugs present a significant riskof ventricular pro-arrhythmia in the hours-days following chemicalcardioversion. The ventricular pro-arrhythmia observed followingattempted (successful or unsuccessful) chemical cardioversion of AF istypically polymorphic ventricular tachycardia (e.g.,Torsade-de-Pointes). Torsade is known to be exacerbated by ventricularpauses and bradycardia. Importantly, Torsade-de-Pointes can be preventedby pacing modes that eliminate ventricular pauses and bradycardia.

AF patients who are candidates for cardioversion have frequent orrecurring episodes of AF and therefore will require future electrical orchemical cardioversion to maintain normal sinus rhythm. Chemicalcardioversion may allow for the alleviation of AF burden withelimination of the single largest drawback of defibrillationtherapy—patient pain perception. However, the pro-arrhythmia riskassociated with chemical cardioversion is significant (˜5%). As aresult, following chemical cardioversion, patients may remain in thehospital for some number of hours or days to be monitored for thepresence of ventricular arrhythmias.

There exists a need for improved systems and methods for treatingcardiac arrhythmias and other adverse cardiac conditions, includingadverse non-arrhythmic conditions. There exists a further need for suchsystems and methods that address the increased risk of pro-arrhythmiafollowing delivery of chemical cardioversion. The present inventionfulfills these and other needs.

SUMMARY OF THE INVENTION

The present invention is directed to methods and systems for treating anadverse cardiac condition. According to one embodiment, an activationsignal is generated by a patient actuatable non-implanted activator inresponse to the patient sensing a perceived adverse cardiac condition.An implantable medical device implanted within the patient confirms thatthe patient is experiencing an actual adverse cardiac condition. Thenon-implanted activator, in communication with the implantable medicaldevice, generates a perceivable initiating signal instructingcommencement of a drug delivery regimen to treat the actual adversecardiac condition. A safe mode of pacing appropriate for the adversecardiac condition is initiated.

The activation signal is produced in response to the patient sensing theperceived adverse cardiac condition or in response to the implantablemedical device sensing the actual adverse cardiac condition. The safemode of pacing is a pacing mode appropriate for the drug delivered tothe patient and the current condition of the patient. The safe mode ofpacing preferably terminates in response to expiration of a predefinedtimeout period. The predefined timeout period is preferably associatedwith a half-life of a drug delivered to the patient or a sensedresolution of the adverse cardiac condition.

Initiating the safe mode of pacing typically involves pacing one, two,three or four chambers of the patient's heart in accordance with aselected safe pacing mode. The safe mode of pacing may be changed toanother mode of pacing in response to an effect of the drug deliveryregimen on the patient. Also, the safe mode of pacing may be changed toanother mode of pacing in response to an effect of the safe mode ofpacing on the patient. After termination of the actual adverse cardiaccondition, a pacing mode considered normal for the patient is initiated.

In accordance with another embodiment of the present invention, a systemfor treating cardiac arrhythmia or other adverse cardiac conditionincludes a non-implanted activator actuatable by a patient or physicianthat operates in cooperation with an implantable medical deviceimplanted within a patient. The activator includes a communication unitand produces an activation signal in response to a patient sensing aperceived adverse cardiac condition. Alternatively, or in addition, theactivation signal may be produced by the non-implanted activator inresponse to the implantable medical device detecting the cardiaccondition. The implantable medical device includes communicationcircuitry for communicating with the non-implanted activator.

The detection and therapy delivery system of the implantable medicaldevice includes a lead system for detecting cardiac signals anddelivering therapies to the heart. Such therapies may include cardiacpacing, cardioversion or defibrillation. A control system of theimplantable medical device, in response to the activation signal,confirms that the patient is experiencing an actual adverse cardiacevent and generates a confirmation signal. The control system initiatesa pacing regimen to protect against pro-arrhythmic conditions, and thenon-implantable activator generates a perceivable initiating signalinstructing the patient or a physician to commence with a drug deliveryregimen to treat the actual adverse cardiac condition.

The control system, in one configuration, terminates the pacing regimenin response to expiration of a predefined timeout period. The predefinedtimeout period is preferably associated with the half-life of the drugor drugs used in the drug delivery regimen. For example, the predefinedtimeout period may represent a duration of time of at least twice aslong as one half-life of a drug of the drug delivery regimen. Thecontrol system may provide for additional functionality. For example,the control system may initiate electrogram storage in response to theactivation signal or the initiating signal.

In one embodiment, the control system initiates a pacing mode associatedwith a reduced risk of cardiac (e.g., ventricular) arrhythmia for thedrug delivery regimen. For example, the drug delivery regimen mayinclude a number of deliverable drugs, and the control system initiatesa pacing mode associated with a reduced risk of cardiac arrhythmia for aparticular deliverable drug of the drug delivery regimen.

The control system may also change or adjust a mode of the pacingregimen in response to an effect of the drug delivery regimen on thepatient. For example, the control system may change or adjust a mode ofthe pacing regimen after termination of an adverse cardiac condition.

The adverse cardiac condition confirmed by the control system may be anatrial arrhythmic condition. In such a case, the control systemterminates the pacing regimen in response to expiration of a predefinedtimeout period, where the predefined timeout period represents a periodof increased risk of ventricular pro-arrhythmia. The pacing regimenpreferably includes a regimen to treat ventricular pro-arrhythmia, andthe control system initiates a pacing mode associated with a reducedrisk of ventricular pro-arrhythmia. For example, the drug deliveryregimen may include a number of deliverable drugs. The control systemmay change a mode of the pacing regimen to a mode associated with areduced risk of ventricular arrhythmia for a particular deliverable drugof the drug delivery regimen.

In accordance with a further embodiment of the present invention, amethod of treating cardiac arrhythmia involves producing, by use of apatient actuatable non-implanted activator, an activation signal inresponse to a patient sensing a perceived cardiac arrhythmic condition.The method further involves confirming, by communication between thenon-implanted activator and an implantable medical device providedwithin the patient, that the patient is experiencing an actual cardiacarrhythmic condition. A perceivable initiating signal instructing thepatient or a physician to commence a drug delivery regimen to treat theactual cardiac arrhythmic condition is generated by the non-implantedactivator. A pacing, cardioversion or defibrillation regimen (pacingregimen) is initiated to treat the actual cardiac arrhythmic condition.

In accordance with another embodiment of the present invention, a methodof treating atrial arrhythmia involves producing, by use of a patientactuatable non-implanted activator, an activation signal in response toa patient sensing a perceived atrial arrhythmic condition. The methodfurther involves confirming that the patient is experiencing an actualatrial arrhythmic condition. A perceivable initiating signal is thengenerated by the activator to instruct the patient or a physician tocommence with a drug delivery regimen to treat the actual atrialarrhythmic condition. A pacing, cardioversion or defibrillation regimento treat the actual atrial arrhythmic condition is initiated. The pacingregimen preferably accounts for presence of a drug delivered to thepatient as part of the drug delivery regimen.

In accordance with yet another embodiment of the present invention, amethod of treating cardiac arrhythmia involves producing, by use of apatient actuatable non-implanted activator, an activation signal inresponse to sensing a perceived cardiac arrhythmic condition by apatient or an implantable medical device provided within the patient.The method further involves confirming, by communication between thenon-implanted activator and the implantable medical device, that thepatient is experiencing an actual cardiac arrhythmic condition. Aperceivable initiating signal is generated by the non-implantedactivator instructing the patient or a physician to commence with a drugdelivery regimen to treat the actual cardiac arrhythmic condition.

The method may further involve communicating to the patient a particulardrug to administer. A particular dosage of a drug to administer may becommunicated to the patient. The method may involve communicating to thepatient a plurality of reminders to administer a particular drug atspecified times.

According to another embodiment, a method of treating an adverse cardiaccondition involves initiating a safe mode of pacing appropriate fortreating an adverse non-arrhythmic cardiac event or condition. The safemode of pacing can involve pacing one or both of the patient'sventricles to improve pumping efficiency of the patient's heart. Theadverse cardiac condition can be an episode of angina, a heart failuredecompensation event, or an acute ischemic event, for example.

A cardiac management system, according to an embodiment for treatingadverse non-arrhythmic cardiac conditions, includes a detection andtherapy delivery system for detecting cardiac signals and deliveringtherapies appropriate to treat such adverse non-arrhythmic cardiacconditions. Such therapies may include cardiac pacing that increasespumping efficiency of the heart. For example, such therapies can includeleft ventricular pacing or bi-ventricular pacing. A control system ofthe implantable medical device, in response to an activation signal,confirms that the patient is experiencing an actual adversenon-arrhythmic cardiac event and generates a confirmation signal. Thecontrol system initiates a pacing regimen to best address the adversenon-arrhythmic cardiac condition, and the non-implantable activatorgenerates a perceivable initiating signal instructing the patient or aphysician to commence with a drug delivery regimen to treat the actualadverse non-arrhythmic cardiac condition.

The above summary of the present invention is not intended to describeeach embodiment or every implementation of the present invention.Advantages and attainments, together with a more complete understandingof the invention, will become apparent and appreciated by referring tothe following detailed description and claims taken in conjunction withthe accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a partial view of one embodiment of an implantable medicaldevice with an endocardial lead system extending into right atrial andright ventricular chambers of a heart;

FIG. 2 is a partial view of one embodiment of an implantable medicaldevice with an endocardial lead system extending into right and leftatrial and right ventricular chambers of a heart;

FIG. 3 is a block diagram of a cardiac defibrillator with which amethodology for treating a cardiac arrhythmia of the present inventionis implemented;

FIG. 4 shows a non-implantable activator that operates in cooperationwith an implantable medical device in accordance with an embodiment ofthe present invention;

FIG. 5 depicts various processes involving the prevention or terminationof a cardiac arrhythmic condition associated with the administering ofchemical and electrical cardioversion in accordance with an embodimentof the present invention;

FIG. 6 depicts various processes involving the prevention or terminationof a cardiac arrhythmic condition associated with the administering ofchemical cardioversion in accordance with an embodiment of the presentinvention;

FIG. 7 depicts various processes involving the prevention or terminationof a cardiac arrhythmic condition associated with the administering ofchemical and electrical cardioversion in accordance with anotherembodiment of the present invention; and

FIG. 8 depicts various processes involving the detection andconfirmation of an adverse cardiac condition, and transitioning to asafe mode of pacing appropriate for the detected adverse cardiaccondition in accordance with another embodiment of the presentinvention.

While the invention is amenable to various modifications and alternativeforms, specifics thereof have been shown by way of example in thedrawings and will be described in detail hereinbelow. It is to beunderstood, however, that the intention is not to limit the invention tothe particular embodiments described. On the contrary, the invention isintended to cover all modifications, equivalents, and alternativesfalling within the scope of the invention as defined by the appendedclaims.

DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS

In the following description of the illustrated embodiments, referencesare made to the accompanying drawings which form a part hereof, and inwhich is shown by way of illustration, various embodiments in which theinvention may be practiced. It is to be understood that otherembodiments may be utilized, and structural and functional changes maybe made without departing from the scope of the present invention.

The embodiments of the present system illustrated herein are generallydescribed as being implemented in an implantable cardiac defibrillator,which may operate in numerous pacing modes known in the art. The systemsand methods of the present invention may also be implemented in otherimplantable medical devices that sense cardiac activity, such aspacemakers and cardiac monitors, for example. Such implantable medicaldevices may be single and multiple heart chamber devices. For example,the invention may be implemented using a pacemaker, defibrillator,resynchronizer, cardioverter, or combination of such devices for singleor multiple chamber applications. In one particular embodiment, thepresent invention is implemented in an implantable atrialcardioverter/defibrillator. The systems and methods of the presentinvention may also be implemented, in part, in externalcardioverter/monitor systems, programmers, and other non-implantablesystems operable by a physician and/or a patient.

The present invention provides for systems and methods that monitor,moderate, or both monitor and moderate cardiac activity for patients whoare taking anti-arrhythmic drugs or other drugs prescribed to treat apatient's anomalous cardiac condition. Systems and methods of thepresent invention also provide for monitoring, moderation, or bothmonitoring and moderation of cardiac activity for patients who aresuffering from adverse non-arrhythmic heart conditions and taking drugsprescribed to treat adverse cardiac activity associated with suchnon-arrhythmic heart conditions.

Depending on the nature of the drug regimen, a patient may besusceptible to arrhythmias or other adverse cardiac activity as a sideeffect of the administered drug. In one embodiment, an implantablemedical device provides for selectability between various pacing modes,including pacing modes that account for the increased risk of anarrhythmia developing during the effectiveness period of a particulardrug delivered to the patient. In another embodiment, an implantablemedical device provides for selectability between various pacing modesto improve pumping efficiency of the heart during the effectivenessperiod of a particular drug delivered to the patient.

In accordance with another embodiment, a non-implanted activator is usedby the patient or physician to interact with the implantable medicaldevice provided within the patient. Upon sensing the onset of a cardiacarrhythmic event or other adverse cardiac condition, the patientactuates the activator which communicatively cooperates with theimplantable medical device to confirm the presence of an actual adversecardiac condition, communicate such confirmation to the patient as apatient perceivable signal indicating that a particular chemicalcardioversion drug regimen is to be initiated, and initiate a pacingregimen appropriate for the particular chemical cardioversion drugregimen.

The range of drugs defining a given drug therapy regimen may be variedaccording to the type and nature of a given patient's particular cardiaccondition. In the case of atrial fibrillation, for example, anappropriate drug regimen may include any one or a combination ofanti-arrhythmic (AA) agents that have been approved for the chemicaltreatment of atrial fibrillation. A non-exhaustive, non-limiting list ofsuch AA agents includes: quinidine, procainamide, disopyramide,flecaininde, propafenone, moricizine, sotalol, amiodarone, ibutilide,and dofetilide (e.g., class III anti-arrhythmic agents).

The activator may also be actuated by the patient to selectivelyinitiate and terminate storage of electrograms. The pacing regimencontinues for at least a period of time during which the delivered druginfluences the patient's cardiac activity, such as a time period definedby several drug half lives. The pacing regimen may, for example,continue beyond the time in which chemical cardioversion terminates thearrhythmic condition. The QT interval may be monitored by theimplantable medical device to determine the effectiveness and/orinfluence of a cardioversion drug delivered to the patient.

The implantable medical device may include at least one atrial and oneventricular pace/sense lead. The pacing modes of the implantable medicaldevice include pacing modes that reduce the likelihood of pro-arrhythmiafollowing attempted chemical cardioversion. For example, the implantablemedical device may include rate-smoothing algorithms to preventventricular pauses and bradycardia (e.g., VRR, Sudden Brady Response).

In the specific case of atrial fibrillation (AF), for example, thepacing modes include those that provide for a reduced risk ofpolymorphic ventricular tachycardia onset (e.g., Torsade-de-Pointes)following attempted chemical cardioversion. Torsade-de-Pointes can beprevented by implementing pacing modes that eliminate ventricular pausesand bradycardia. The implantable medical device may provide for theselection of additional operating modes, such as burst pacing modes fortachycardia termination, atrial ATP (antitachycardia pacing) modes,including burst, decrement, and scan modes, and standard pacing modes,such as DDD, VVI, VVIR, among others.

Referring now to FIG. 1 of the drawings, there is shown one embodimentof a medical device system with which the present invention may beimplemented. The system includes an implantable cardiac defibrillator100 electrically and physically coupled to an intracardiac lead system102. The intracardiac lead system 102 is implanted in a human body withportions of the intracardiac lead system 102 inserted into a heart 106.The intracardiac lead system 102 is used to detect and analyze electriccardiac signals produced by the heart 106 and to provide electricalenergy to the heart 106 under certain predetermined conditions to treatcardiac arrhythmias, including, for example, atrial arrhythmias andventricular arrhythmias associated with ventricular pro-arrhythmia.

The intracardiac lead system 102 includes one or more pacing electrodesand one or more intracardiac defibrillation electrodes. In theparticular embodiment shown in FIG. 1, the intracardiac lead system 102includes a ventricular lead system 104 and an atrial lead system 106.The ventricular lead system 104 includes an SVC-coil 116, an RV-coil114, and an RV-tip electrode 112. The RV-coil 114, which is alsoreferred to as an RV-ring electrode, is spaced apart from the RV-tipelectrode 112, which is a pacing electrode. In one embodiment, theventricular lead system 104 is configured as an integrated bipolarpace/shock lead. The atrial lead system 106 includes an A-tip electrode152 and an A-ring electrode 154. In one embodiment, the atrial leadsystem 106 is configured as an atrial J lead.

In this configuration, the intracardiac lead system 102 is positionedwithin the heart 106, with a portion of the atrial lead system 106extending into the right atrium 120 and portions of the ventricular leadsystem 104 extending into the right atrium 120 and right ventricle 118.In particular, the A-tip electrode 152 and A-ring electrode 154 arepositioned at appropriate locations within the right atrium 120. TheRV-tip electrode 112 and RV-coil 114 are positioned at appropriatelocations within the right ventricle 118. The SVC-coil 116 is positionedat an appropriate location within the right atrium chamber 120 of theheart 106 or a major vein leading to the right atrium chamber 120 of theheart 106. The RV-coil 114 and SVC-coil 116 depicted in FIG. 1 aredefibrillation electrodes.

Additional or different pacing and defibrillation electrodes can beincluded on the intracardiac lead system 102 to allow for variousbipolar sensing, pacing, and defibrillation capabilities. For example,the intracardiac lead system 102 may include endocardial pacing andcardioversion/defibrillation leads (not shown) that are advanced intothe coronary sinus and coronary veins to locate the distal electrode(s)adjacent to the left ventricle or the left atrium. The distal end ofsuch coronary sinus leads is advanced through the superior vena cava,the right atrium, the valve of the coronary sinus, the coronary sinus,and into a coronary vein communicating with the coronary sinus, such asthe great vein. Other intracardiac lead and electrode arrangements andconfigurations known in the art are also possible and considered to bewithin the scope of the present system.

By way of particular example, FIG. 2 illustrates another embodiment ofan implantable lead system of the type described immediately above. Theportions of the heart illustrated in FIG. 2 are the right ventricle 312,the left ventricle 314, the right atrium 316, the left atrium 318, thesuperior vena cava 320, the coronary sinus channel 321 which, as usedherein, denotes the coronary sinus 322 and the great cardiac vein 323,the coronary sinus ostium or opening 324, the left ventricular free wall326, and the inferior vena cava 327.

Extending into the heart are an endocardial first lead 334 and anintravascular second lead 336. The endocardial first lead 334 preferablycomprises an endocardial bi-polar lead having electrodes 338 and 340arranged for establishing electrical contact with the right ventricle312 of the heart. The electrodes 338 and 340 permit bi-polar sensing ofventricular activations in the right ventricle. As illustrated, the lead334 is preferably fed through the superior vena cava 320, into the rightatrium 316 and then into the right ventricle 312.

The second lead 336 generally includes a first or tip electrode 344 anda second or proximal electrode 346. As illustrated, the second lead 336is flexible and arranged to be passed down the superior vena cava 320,into the right atrium 316, into the coronary sinus ostium 324, andadvanced into the coronary sinus channel 321 of the heart near the leftside thereof so that the first or tip electrode 344 is within thecoronary sinus channel 321 either within the coronary sinus 322 adjacentthe left ventricle 314 and beneath the left atrium 318 or within thegreat cardiac vein 323 adjacent the left ventricle 314 and beneath theleft atrium 318. The electrodes 344 and 346 are spaced apart such thatwhen the first electrode 344 is positioned as described above, thesecond electrode 346 is in the right atrium 316.

In this configuration, the first electrode 344 together with the secondelectrode 346 provide bi-polar sensing of heart activity in the atria316 and 318. The first electrode 344 and the second electrode 346further provide for the delivery of defibrillating or cardiovertingelectrical energy to the atria. The lead arrangement depicted in FIG. 2may be used in conjunction with the IMD circuitry shown in FIG. 3 orthat disclosed in commonly owned U.S. Pat. No. 5,999,851, which ishereby incorporated herein by reference.

Returning now to FIG. 1, the ventricular and atrial lead systems 104,106 include conductors for communicating sense, pacing, anddefibrillation signals between the cardiac defibrillator 100 and theelectrodes and coils of the lead systems 104, 106. As is shown in FIG.1, ventricular lead system 104 includes a conductor 108 for transmittingsense and pacing signals between the RV-tip electrode 112 and an RV-tipterminal 202 within the cardiac defibrillator 100. A conductor 110 ofthe ventricular lead system 104 transmits sense signals between theRV-coil or ring electrode 114 and an RV-coil terminal 204 within thecardiac defibrillator 100. The ventricular lead system 104 also includesconductors 122, 124 for transmitting sense and defibrillation signalsbetween terminals 206, 208 of the cardiac defibrillator 100 and SVC- andRV-coils 116 and 114, respectively. The atrial lead system 106 includesconductors 132, 134 for transmitting sense and pacing signals betweenterminals 210, 212 of the cardiac defibrillator 100 and A-tip and A-ringelectrodes 152 and 154, respectively.

Referring now to FIG. 3, there is shown an embodiment of a cardiacdefibrillator 100 with which embodiments of the present invention may bepracticed. The cardiac defibrillator 100 shown in FIG. 3 will bedescribed within the context of the lead arrangement depicted in FIG. 1,it being understood that cardiac defibrillator 100 or variations thereofmay also be deployed to accommodate the lead arrangement depicted inFIG. 2 or various other lead arrangements as are known in the art.

The cardiac defibrillator 100 includes control system circuitry 101 forreceiving cardiac signals from a heart 106 and delivering electricalenergy to the heart 106. The control system circuitry 101 includesterminals 202, 204, 206, 208, 209, 210, and 212 for connecting to theelectrodes and coils of the intracardiac lead system 102, as previouslydiscussed.

In one embodiment, the control system circuitry 101 of the cardiacdefibrillator 100 is encased and hermetically sealed in a housing 130suitable for implanting in a human body as is known in the art. Power tothe cardiac defibrillator 100 is supplied by an electrochemical battery256 that is housed within the cardiac defibrillator 100. A connectorblock (not shown) is additionally attached to the housing 130 of thecardiac defibrillator 100 to allow for the physical and electricalattachment of the intracardiac lead system conductors to the cardiacdefibrillator 100 and the encased control system circuitry 101.

In one embodiment, the control system circuitry 101 of the cardiacdefibrillator 100 is a programmable microprocessor-based system, with acontroller 216 and a memory circuit (not shown). The memory circuitcontains parameters for various pacing, defibrillation, and sensingmodes and stores data indicative of cardiac signals received by thecontrol system circuitry 101. The controller 216 and memory circuitcooperate with other components of the control system circuitry 101 toperform operations involving the monitoring, moderating, and terminationof cardiac arrhythmias that develop during or after delivery of ananti-arrhythmic agent according to the principles of the presentinvention, in addition to other sensing, pacing and defibrillationfunctions. A memory 213 is also provided for storing historical EGM andtherapy data, which may be used on-board for various purposes andtransmitted to an external programmer unit (not shown) as needed ordesired.

Telemetry circuitry 224 is additionally coupled to the control systemcircuitry 101 to allow the cardiac defibrillator 100 to communicate withan external communicating device, such as a hand-held activator 300 or,if appropriate or desired, a programmer unit (not shown). In oneembodiment, the telemetry circuitry 224 and the activator 300 use a wireloop antenna and a radio frequency telemetric link, as is known in theart, to receive and transmit signals and data between the activator 300and the control system circuitry 101. In this manner, various commands,data, and other signals are communicated between the activator 300 andthe controller 216 of the cardiac defibrillator 100.

Cardiac signals sensed through use of the RV-tip electrode 112 arenear-field signals or rate channel signals as are known in the art. Moreparticularly, a rate channel signal is detected as a voltage developedbetween the RV-tip electrode 112 and the RV-coil 114. Cardiac signalssensed through use of one or both of the defibrillation coils orelectrodes 114, 116 are far-field signals, also referred to asmorphology or shock channel signals, as are known in the art. Shockchannel signals developed using appropriate combinations of the RV-coil,SVC-coil, and can electrodes 114, 116 and 209 are sensed and amplifiedby a shock EGM amplifier 238, the output of which is coupled to thetachyarrythmia detector 250.

In the embodiment of the cardiac defibrillator 100 depicted in FIG. 3,RV-tip and RV-coil electrodes 112, 114 are shown coupled to a V-senseamplifier 230. Rate channel signals received by the V-sense amplifier230 are communicated to an R-wave detector 236. The R-wave detector 236serves to sense and amplify the rate channel signals (e.g., R-waves) andcommunicate the detected signals to a pacemaker 240 and a tachyarrythmiadetector 250.

A-tip and A-ring electrodes 152, 154 are shown coupled to an A-senseamplifier 220. Atrial sense signals received by the A-sense amplifier220 are communicated to an A-wave detector 222, which serves to senseand amplify the A-wave signals. The atrial signals are communicated fromthe A-wave detector 222 to the pacemaker 240 and the tachyarrythmiadetector 250. The pacemaker 240 communicates pacing signals to theRV-tip and A-tip electrodes 112 and 152 according to a preestablishedpacing regimen under appropriate conditions. Blanking circuitry (notshown) is employed in a known manner when a ventricular or atrial pacingpulse is delivered, such that the ventricular channel, atrial channel,and shock channel are properly blanked at the appropriate time and forthe appropriate duration.

The implantable medical devices and non-implantable activator describedwith reference to FIGS. 1-3 are well-suited for implementing embodimentsof the present invention. An embodiment of the activator 300 shown inFIG. 3 is depicted in greater detail in FIG. 4. According to theembodiment shown in FIG. 4, a non-implantable activator 300 is providedin a housing 360 configured for portability and ease of use by thepatient. The activator 300 includes a display 362, such as an LCDdisplay, a speaker 374, and a vibration unit 380 for communicatingvisual, aural, and tactile information, respectively, to the patient. Acontroller 384, such as a microprocessor, and memory 382 are providedwithin the housing 360. A battery 378 provides power to the activecomponents of the activator 300.

A control panel 364 is provided on the housing 360 and includes a numberof user actuatable switches. As shown, the control panel 364 of theactivator 300 includes a mode switch 366 and a status query switch 370.The mode switch 366 provides for user selectability between variousactivator operational modes and, in particular, a number of pacingmodes. The status query switch 370 provides for the presentation ofvarious types of status information, including, for example, implantablemedical device status data, patient physiology data, and activatorrelated data.

An activation LED 372 provides a visual indication that the patient hasactivated the cardiac arrhythmia response capabilities provided to thepatient, such as electrical cardioversion capabilities provided by theimplantable medical device and chemical cardioversion capabilities to beadministered by the patient. In response to the patient sensing onset ofa perceived cardiac arrhythmic condition, the activation switch 368 isactuated by the patient, which results in illumination of activation LED372. Illumination of activation LED 372 unambiguously indicates thepatient's perception of the onset of a cardiac arrhythmic episode andthe patient's intent to initiate the anti-arrhythmia capabilities madeavailable to the patient.

The activator 300 communicates with the implantable medical device via atransceiver 386, which includes an antenna. The transceiver 386communicates with the telemetry circuitry of the implantable medicaldevice to uplink and downlink information therebetween in a manner knownin the art. The implantable medical device, for example, receives anactivation signal that is generated by the controller 384 andtransmitted by the transceiver 386 of the activator 300. The activationsignal is received by the implantable medical device, which confirms thepresence of an actual cardiac arrhythmia. If an actual cardiacarrhythmia is confirmed, the implantable medical device transmits aconfirmation signal to the activator 300, which is received bytransceiver 386. A message is presented on display 362 of the activator300 to communicate to the patient that the implantable medical devicehas detected an actual cardiac arrhythmia. The activation LED 372 orother LED may also illuminate in a particular manner or color to alertthe patient that the perceived cardiac arrhythmia has been confirmed asan actual arrhythmic event.

Upon confirming an actual cardiac arrhythmic condition, an initiationLED 371 is illuminated to instruct the patient that a prescribed drugregimen is to be administered. The activation LED 372 may be deactivatedupon illumination of the initiation LED 371. It is understood thatactivation and initiation LEDs 372, 371 may be substituted by use of asingle LED or other annunciator capable of transitioning between atleast two visually perceivable states (e.g., color states, illuminationor blinking states).

A communications interface 376, such as a network interface connector orwireless communications interface, provides for connectivity between theportable activator 300 and a network. The communications interface 376provides the ability to communicate stored information acquired by theactivator 300 and the patient's implantable medical device to aphysician's office or hospital for evaluation.

The communications interface 376 also allows the physician to obtainreal-time information (e.g., electrocardiogram, physiologic,IMD/activator operational data) via an active communications linkestablished between the network, activator 300 (via communicationsinterface 376), and implantable medical device (via transceiver 386).Further, the physician may also send instructions (e.g., commands,software changes and updates) to the activator 300 and/or implantablemedical device to alter the operation of the activator 300 and/orimplantable medical device.

The switch panel 364 of the activator 300 may also include a drug dataswitch 369. The drug data switch 369 provides for the selection andpresentation of various drug related data on the display 362. The drugrelated data may, for example, indicate the required or recommended drugof a drug regimen to be administered by the patient in response to theimplantable medical device confirming the onset of an actual cardiacarrhythmic condition. Logic of the activator 300 may suggest aprioritized listing of drugs and/or drug dosages to be delivered basedon a physician's recommendation or prescription. The drug recommendationand/or drug dosage may be adjusted by the activator logic in response tothe actual cardiac arrhythmic condition sensed by the implantablemedical device.

In this regard, real-time data acquired by the implantable medicaldevice may be used by the activator 300 to refine activatorrecommendations concerning drug dosages, time between dosage deliveries,and specific drugs. Also, the patient may be provided with severityinformation, such that the relative severity of the arrhythmic conditionis communicated to the patient, including, for example, warnings thatimmediate physician intervention is required.

The controller 384, memory 382, display 362, and switches of the controlpanel 364 (several of which are not shown, such as enter, scroll, andcursor movement keys) provide for user friendly navigation of menus andfunctions provided by the activator 300. These and other components ofthe activator 300 described above may be modified in form and functiondepending on the requirements of the system. For example, several of theabove described components and functions may be included or excludeddepending on the system design requirements.

Turning now to FIG. 5, there is illustrated various processes involvingthe prevention or termination of a cardiac arrhythmic conditionassociated with the administering of chemical cardioversion. In thisembodiment, the patient is viewed as a sensor, in that the patient cantypically sense 400 the onset or presence of a cardiac arrhythmia.Alternatively, the implantable medical device provided within thepatient may sense 400 the onset or presence of a cardiac arrhythmia.

In response to sensing the onset or presence of a cardiac arrhythmia, apro-arrhythmia compensating pacing mode is activated 402. Such a pacingmode is one that accounts for the increased risk of an arrhythmiadeveloping during the effectiveness period of a particular drugdelivered to the patient. The patient confirms 404 that the prescribeddrug has been administered (e.g., via oral, intravenous, skin patch,nasal, or other means). The chemical cardioversion procedure ismonitored 406. The pacing mode is maintained, or a more effective modeis selected, until a predefined time duration has expired 408. Astandard pacing mode may be selected and initiated after the risk ofpro-arrhythmia has reduced.

FIG. 6 depicts various processes involving the prevention or terminationof a cardiac arrhythmic condition associated with the administering ofchemical cardioversion in accordance with another embodiment of thepresent invention. In this embodiment, the patient or implantablemedical device senses 420 a cardiac arrhythmic condition. The patientthen actuates 422 an external activator. The activator generates anactivation signal which is received 424 by the implantable medicaldevice. The implantable medical device confirms 426 the presence of acardiac arrhythmic condition, such as by monitoring the time betweensuccessive R-waves, referred to as RR intervals, or by other means knownin the art. For example, an RR interval may be measured as an intervalbetween Vs to Vs, Vs to Vp, Vp to Vs, or Vp to Vp events, where Vs isthe ventricular sensed event detection time and Vp is the ventricularpace pulse delivery time.

The implantable medical device generates and transmits a confirmationsignal in response to confirming an actual arrhythmic condition. Theconfirmation signal transmitted by the implantable medical device isreceived by the external activator. An initiation signal perceivable bythe patient is produced 428 by the external activator in response to thereceived confirmation signal. The initiation signal is preferably avisual signal (LED, message display, icon display, etc.), but may alsobe an audio or tactile signal, or a combination of these signal types.The patient, in response to the initiation signal, is prompted tocommence 428 the prescribed drug delivery regimen. The implantablemedical device monitors 430 the effectiveness of the drug deliveryregimen. The efficacy of the administered cardioversion drug regimen iscommunicated in visual or auditory form to the patient, typically on arepeated basis over the duration of the chemical cardioversionprocedure. The patient may, for example, query the implantable medicaldevice using the external activator to obtain various types of datarelating to the chemical cardioversion procedure.

FIG. 7 depicts various processes involving the prevention or terminationof a cardiac arrhythmic condition associated with the administering ofchemical cardioversion in accordance with a further embodiment of thepresent invention. As in the embodiment depicted in FIG. 6, the patientor implantable medical device senses 440 a cardiac arrhythmic conditionand, in response, actuates 442 an external activator. The activationsignal generated by the activator is received 444 by the implantablemedical device. The implantable medical device confirms 446 the presenceof a cardiac arrhythmic condition.

According to this embodiment, the implantable medical device initiates448 a pacing regime appropriate for the patient and the type of chemicalcardioverting drugs that the patient or doctor will be administering. Anappropriate pacing regime is one that reduces the risk of an arrhythmiadeveloping during the effectiveness period of a particular drugdelivered to the patient.

The implantable medical device transmits a confirmation signal to theexternal activator in response to confirming an actual arrhythmiccondition. The external activator generates 450 an initiation signalperceivable by the patient in response to the received confirmationsignal. The patient, in response to the initiation signal, is promptedto commence 450 the prescribed drug delivery regimen. The implantablemedical device monitors 452 the effectiveness of the drug deliveryregimen and communicates the efficacy of the administered cardioversiondrug regimen to the patient.

Devices and methods implemented in accordance with the principles of thepresent invention can be employed to treat a wide variety of adversecardiac conditions in addition to those discussed hereinabove. Suchadverse cardiac conditions include both arrhythmic and non-arrhythmicconditions, including heart failure conditions, decompensation events,tachycardia conditions, bradycardia conditions, acute ischemic events(e.g., myocardial infarction), and episodes of angina, for example.

In the context of an embodiment of the present invention, it is assumedthat a patient who is susceptible to one or more of these or otheradverse cardiac condition(s) is currently being treated with anappropriate drug delivery regimen as prescribed by a physician. Inaddition, it is assumed that a cardiac management device implanted inthe patient has been programmed, or is capable of being dynamicallyprogrammed, to operate in one or more safe pacing modes appropriate forone or more particular adverse cardiac conditions and appropriate forthe prescribed drug delivery regimen.

FIG. 8 depicts various processes involving the detection andconfirmation of an adverse cardiac condition experienced by a givenpatient, and the patient-assisted transitioning of an implanted cardiacmanagement device to a safe mode of pacing appropriate for the detectedadverse cardiac condition and prescribed drug therapy in accordance withan embodiment of the present invention. The processes shown in FIG. 8are initially implicated when a patient senses 500 an adverse cardiaccondition, such as one of the adverse cardiac events listed above. Inresponse to perceiving the adverse cardiac condition, the patientactivates 502 an external activator in a manner previously described.

The implanted cardiac management device, in response to patientactivation of the external activator, confirms 504 that the patient isexperiencing an actual adverse cardiac condition. Upon confirming thepresent occurrence of the adverse cardiac condition, the implantedcardiac management device generates 506 a signal indicating that a drugdelivery regimen is to be commenced (e.g., taking of nitroglycerin inthe case of a myocardial infarction event). The external activatorreceives this signal and, in response, communicates a drug deliverycommencement message (e.g., audio, visual, and/or tactile message) tothe patient.

In the case of congestive heart failure, for example, the patient may bedirected by the external activator to take an ACE inhibitor, β-blocker,diuretic or dosage of spironalactone, for example, as prescribed by thepatient's physician. In the case of angina or myocardial infarction, byway of further example, the external activator may direct the patient totake aspirin, nitroglycerin or other drug that dilates heart vessels aspreviously prescribed.

The implanted cardiac management device transitions 508 to a safe pacingmode appropriate for the detected adverse cardiac condition and the drugtherapy delivered to the patient. The implanted cardiac managementdevice determines 510 whether or not the safe pacing mode is effectingproper pacing of the heart to treat the detected adverse cardiaccondition. The implanted cardiac management device can transition toanother pacing mode if the current pacing mode is not effectivelytreated the adverse cardiac condition.

In the case of certain adverse non-arrhythmic cardiac conditions, suchas an episode of angina, a heart failure decompensation event ormyocardial infarction, for example, the implanted cardiac managementdevice transitions 508 to a safe pacing mode which provides for anincrease in pumping efficiency of the heart. For example, the implantedcardiac management device can transition to a left ventricular pacingmode or a bi-ventricular pacing mode as is known in the art for purposesof increasing the hemodyamic efficiency or output of the heart.

Subsequent to the patient taking the prescribed medication, theimplanted cardiac management device monitors cardiac activity to confirm512 that the drug delivery regimen is effectively treating the adversecardiac condition. For example, the implanted cardiac management devicecontinues operating in the safe pacing mode(s) and monitoring cardiacactivity for a duration of time equal to or exceeding several half-livesof the drug or drugs taken by the patient as part of the prescribed drugdelivery regimen. Assuming that the adverse cardiac condition has beeneffectively treated, such as by not detecting the reoccurrence of theadverse condition for several drug half-lives, the implanted cardiacmanagement device can transition to normal pacing mode programmingspecified for the patient.

It will, of course, be understood that various modifications andadditions can be made to the preferred embodiments discussed hereinabovewithout departing from the scope of the present invention. Accordingly,the scope of the present invention should not be limited by theparticular embodiments described above, but should be defined only bythe claims set forth below and equivalents thereof.

1. A method of treating cardiac arrhythmia, comprising: producing, byuse of a patient actuatable non-implanted activator, an activationsignal in response to a patient sensing a perceived cardiac arrhythmiccondition; confirming, by an implantable medical device provided withinthe patient, that the patient is experiencing an actual cardiacarrhythmic condition; generating, by the non-implanted activator incommunication with the implantable medical device, a perceivableinitiating signal instructing the patient or a physician to commencewith a drug delivery regimen to treat the actual cardiac arrhythmiccondition; and initiating a pacing regimen to treat the actual cardiacarrhythmic condition.
 2. The method of claim 1, wherein the pacingregimen terminates in response to expiration of a predefined timeoutperiod.
 3. The method of claim 2, wherein the predefined timeout periodis associated with a half-life of a drug of the drug delivery regimen.4. The method of claim 1, wherein the pacing regimen terminates inresponse to expiration of a predefined timeout period, the predefinedtimeout period representing a duration of time of greater than onehalf-life of a drug of the drug delivery regimen.
 5. The method of claim1, wherein the activation signal is produced by use of the non-implantedactivator in response to the patient sensing the perceived cardiacarrhythmic condition or in response to the implantable medical devicesensing the actual cardiac arrhythmic condition.
 6. The method of claim1, wherein initiating the pacing regimen further comprises pacing one ormore of the patient's atria and ventricles.
 7. The method of claim 1,further comprising initiating electrogram storage in response to theactivation signal or the initiating signal.
 8. The method of claim 1,wherein initiating the pacing regimen further comprises initiating apacing mode associated with a reduced risk of cardiac arrhythmia for thedrug delivery regimen.
 9. The method of claim 1, wherein the drugdelivery regimen comprises a plurality of deliverable drugs, and whereininitiating the pacing regimen further comprises initiating a pacing modeassociated with a reduced risk of cardiac arrhythmia for a particulardeliverable drug of the drug delivery regimen.
 10. The method of claim1, further comprising changing a mode of the pacing regimen in responseto an effect of the drug delivery regimen on the patient.
 11. The methodof claim 1, further comprising changing a mode of the pacing regimenafter termination of the actual cardiac arrhythmic condition by deliveryof one or both of the pacing regimen and the drug delivery regimen. 12.A method of treating atrial arrhythmia, comprising: producing, by use ofa patient actuatable non-implanted activator, an activation signal inresponse to a patient sensing a perceived atrial arrhythmic condition;confirming that the patient is experiencing an actual atrial arrhythmiccondition; generating, by the non-implanted activator, a perceivableinitiating signal instructing the patient or a physician to commencewith a drug delivery regimen to treat the actual atrial arrhythmiccondition; and initiating a pacing regimen to treat the actual atrialarrhythmic condition, the pacing regimen accounting for presence of adrug delivered to the patient as part of the drug delivery regimen. 13.The method of claim 12, wherein the pacing regimen terminates inresponse to expiration of a predefined timeout period, the predefinedtimeout period associated with a half-life of a drug of the drugdelivery regimen.
 14. The method of claim 12, wherein the pacing regimenterminates in response to expiration of a predefined timeout period, thepredefined timeout period representing a duration of time of greaterthan one half-life of a drug of the drug delivery regimen.
 15. Themethod of claim 12, wherein the pacing regimen terminates in response toexpiration of a predefined timeout period, the predefined timeout periodrepresenting a period of increased risk of ventricular pro-arrhythmia.16. The method of claim 12, further comprising initiating electrogramstorage in response to the activation signal or the initiating signal.17. The method of claim 12, wherein initiating the pacing regimenfurther comprises pacing one or both of the patient's atrium andventricle.
 18. The method of claim 12, wherein the pacing regimencomprises a regimen to treat ventricular pro-arrhythmia.
 19. The methodof claim 12, wherein initiating the pacing regimen further comprisesinitiating a pacing mode associated with a reduced risk of ventricularpro-arrhythmia.
 20. The method of claim 12, further comprising changinga mode of the pacing regimen in response to an effect of the drugdelivery regimen on the patient.
 21. The method of claim 12, wherein thedrug delivery regimen comprises a plurality of deliverable drugs, themethod further comprising changing a mode of the pacing regimen to amode associated with a reduced risk of ventricular arrhythmia for aparticular deliverable drug of the drug delivery regimen.
 22. A methodof treating cardiac arrhythmia, comprising: producing, by use of apatient actuatable non-implanted activator, an activation signal inresponse to sensing a perceived cardiac arrhythmic condition by apatient or an implantable medical device provided within the patient;confirming, by the implantable medical device, that the patient isexperiencing an actual cardiac arrhythmic condition; and generating, bythe non-implanted activator in communication with the implanted medicaldevice, a perceivable initiating signal instructing the patient or aphysician to commence with a drug delivery regimen to treat the actualcardiac arrhythmic condition.
 23. The method of claim 22, furthercomprising communicating to the patient a particular drug to administer.24. The method of claim 22, further comprising communicating to thepatient a particular dosage of a drug to administer.
 25. The method ofclaim 22, further comprising communicating to the patient a plurality ofreminders to administer a particular drug at specified times.
 26. Asystem for treating cardiac arrhythmia, comprising: a non-implantedactivator actuatable by a patient, the activator comprising acommunication unit and producing an activation signal in response to apatient sensing a perceived cardiac arrhythmic condition; and animplantable medical device, comprising: communication circuitry forcommunicating with the non-implanted activator; an energy detection anddelivery system, comprising a lead system, for detecting cardiac signalsand delivering energy to the heart in accordance with a pacing regimen;and a control system, the control system, in response to the activationsignal, confirming that the patient is experiencing an actual cardiacarrhythmic condition and generating a confirmation signal, the controlsystem initiating the pacing regimen to treat the actual cardiacarrhythmic condition, and the non-implantable activator generating aperceivable initiating signal instructing the patient or a physician tocommence with a drug delivery regimen to treat the actual cardiacarrhythmic condition.
 27. The system of claim 26, wherein the controlsystem terminates the pacing regimen in response to expiration of apredefined timeout period.
 28. The system of claim 27, wherein thepredefined timeout period is associated with a half-life of a drug ofthe drug delivery regimen.
 29. The system of claim 26, wherein thecontrol system terminates the pacing regimen in response to expirationof a predefined timeout period, the predefined timeout periodrepresenting a duration of time of at least twice as long as onehalf-life of a drug of the drug delivery regimen.
 30. The system ofclaim 26, wherein the activation signal is produced by the non-implantedactivator in response to the patient sensing the perceived cardiacarrhythmic condition or by the control system in response to detectingthe actual cardiac arrhythmic condition.
 31. The system of claim 26,wherein the control system initiates electrogram storage in response tothe activation signal or the initiating signal.
 32. The system of claim26, wherein the control system initiates a pacing mode associated with areduced risk of cardiac arrhythmia for the drug delivery regimen. 33.The system of claim 26, wherein the drug delivery regimen comprises aplurality of deliverable drugs, and the control system initiates apacing mode associated with a reduced risk of cardiac arrhythmia for aparticular deliverable drug of the drug delivery regimen.
 34. The systemof claim 26, wherein the control system changes a mode of the pacingregimen in response to an effect of the drug delivery regimen on thepatient.
 35. The system of claim 26, wherein the control system changesa mode of the pacing regimen after termination of the actual cardiacarrhythmic condition by delivery of one or both of the pacing regimenand the drug delivery regimen.
 36. The system of claim 26, wherein theactual cardiac arrhythmia is an atrial arrhythmic condition, and thecontrol system terminates the pacing regimen in response to expirationof a predefined timeout period, the predefined timeout periodrepresenting a period of increased risk of ventricular pro-arrhythmia.37. The system of claim 26, wherein the actual cardiac arrhythmia is anatrial arrhythmic condition, and the pacing regimen comprises a regimento treat ventricular pro-arrhythmia.
 38. The system of claim 26, whereinthe actual cardiac arrhythmia is an atrial arrhythmic condition, and thepacing regimen further comprises initiating a pacing mode associatedwith a reduced risk of ventricular pro-arrhythmia.
 39. The system ofclaim 26, wherein the actual cardiac arrhythmia is an atrial arrhythmiccondition and the drug delivery regimen comprises a plurality ofdeliverable drugs, the control system changing a mode of the pacingregimen to a mode associated with a reduced risk of ventriculararrhythmia for a particular deliverable drug of the drug deliveryregimen.
 40. A method of treating an adverse cardiac condition,comprising: producing, by use of a patient actuatable non-implantedactivator, an activation signal in response to a patient sensing aperceived adverse cardiac condition; confirming, by an implantablemedical device provided within the patient, that the patient isexperiencing an actual adverse cardiac condition; generating, by thenon-implanted activator in communication with the implantable medicaldevice, a perceivable initiating signal instructing commencement of adrug delivery regimen to treat the actual adverse cardiac condition; andinitiating a safe mode of pacing appropriate for the adverse cardiaccondition.
 41. The method of claim 40, wherein the safe mode of pacingcomprises a pacing mode appropriate for a drug of the drug deliveryregimen delivered to the patient.
 42. The method of claim 40, whereinthe safe mode of pacing terminates in response to expiration of apredefined timeout period.
 43. The method of claim 42, wherein thepredefined timeout period is associated with a half-life of a drug ofthe drug delivery regimen.
 44. The method of claim 40, wherein theactivation signal is produced in response to the patient sensing theperceived adverse cardiac condition or in response to the implantablemedical device sensing the actual adverse cardiac condition.
 45. Themethod of claim 40, wherein initiating the safe mode of pacing furthercomprises pacing a plurality of the patient's atria and ventricles. 46.The method of claim 40, wherein initiating the safe mode of pacingfurther comprises pacing one or both of the patient's ventricles toimprove pumping efficiency of the patient's heart.
 47. The method ofclaim 40, further comprising changing the safe mode of pacing to asubsequent mode of energy delivery in response to an effect of the drugdelivery regimen on the patient.
 48. The method of claim 47, wherein thesubsequent mode of energy delivery comprises a pacing, cardioversion ordefibrillation mode.
 49. The method of claim 40, further comprisingchanging the safe mode of pacing to a subsequent mode of energy deliveryin response to an effect of the safe mode of pacing on the patient. 50.The method of claim 49, wherein the subsequent mode of energy deliverycomprises a pacing, cardioversion or defibrillation mode.
 51. The methodof claim 40, further comprising changing from the safe mode of pacing toa normal mode of pacing after termination of the actual adverse cardiaccondition.
 52. The method of claim 40, wherein the adverse cardiaccondition comprises an adverse arrhythmic cardiac event.
 53. The methodof claim 40, wherein the adverse cardiac condition comprises an adversenon-arrhythmic cardiac event.
 54. The method of claim 40, wherein theadverse cardiac condition comprises an episode of angina.
 55. The methodof claim 40, wherein the adverse cardiac condition comprises a heartfailure decompensation event.
 56. The method of claim 40, wherein theadverse cardiac condition comprises an acute ischemic event.
 57. Asystem for treating an adverse non-arrhythmic cardiac condition,comprising: a non-implanted activator actuatable by a patient, theactivator comprising a communication unit and producing an activationsignal in response to a patient sensing a perceived adversenon-arrhythmic cardiac condition; and an implantable medical device,comprising: communication circuitry for communicating with thenon-implanted activator; an energy detection and delivery system,comprising a lead system, for detecting cardiac signals and deliveringenergy to the heart in accordance with a pacing regimen; and a controlsystem, the control system, in response to the activation signal,confirming that the patient is experiencing an actual adversenon-arrhythmic cardiac condition and generating a confirmation signal,the control system initiating the pacing regimen to treat the actualadverse non-arrhythmic cardiac condition, and the non-implantableactivator generating a perceivable initiating signal instructing thepatient or a physician to commence with a drug delivery regimen to treatthe actual adverse non-arrhythmic cardiac condition.
 58. The system ofclaim 57, wherein the control system initiates a pacing mode associatedwith a reduced risk of adverse cardiac activity for the drug deliveryregimen.
 59. The system of claim 57, wherein the control systeminitiates a pacing mode to treat an episode of angina.
 60. The system ofclaim 57, wherein the control system initiates a pacing mode to treat aheart failure decompensation event.
 61. The system of claim 57, whereinthe control system initiates a pacing mode to treat an acute ischemicevent.
 62. The system of claim 57, wherein the control system initiatesa left ventricular pacing mode.
 63. The system of claim 57, wherein thecontrol system initiates a bi-ventricular pacing mode.